Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $9.39 Analyst target: $22.14 Upside: 135.78%
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.